Panic disorder (PD) is a debilitating condition that drives medical spending at least twice as high as medically matched controls. Excessive utilization of healthcare resources comes from emergency department (ED), medications, diagnostic testing, and physician visits. Freespira is an FDA-cleared digital therapeutic that treats PD and panic attacks (PA) by correcting underlying abnormal respiratory physiology. Efficacy of Freespira has been established in prior studies. This paper reports on a quality improvement program that investigated whether treating PD patients with Freespira would reduce medical costs and improve outcomes over 12-months. Panic symptoms were assessed using the Panic Disorder Severity Scale (PDSS). Pre-and post-treatment insurance claims determined costs. At baseline, mean Clinician Global Impression (CGI-S) was 4.4 (moderately/markedly ill), mean PDSS was 14.4 and mean PA frequency/week was 2 (range 0–5). Immediately post-treatment (week 5) mean CGI-S, PDSS and weekly PA frequency declined to 2.8 (borderline/mildly ill, 4.9 (remission) and 0.2 (range 0–2) respectively, p < 0.001. 82% reported PDSS decrease of ≥ 40% (clinically significant), 86% were PA-free. One-year post treatment mean CGI-S, PDSS and PA remained low at 2.1, 4.4, and 0.3 (range 0–1) respectively. 91% had PDSS decrease of ≥ 40%, 73% were PA-free. The majority of patients were panic attack free and/or reduced their symptoms and avoidance behaviors 1-year post Freespira treatment. Mean overall medical costs were reduced by 35% from $548 to $358 PMPM (per member per month) or an annual reduction of $2280. at 12 months post-treatment. There was a 65% reduction in ED costs from $87 to $30 PMPM. Median pharmacy costs were reduced by 68% from $73 to $23 PMPM.

中文翻译：

---

在阿勒格尼健康网络内评估 Freespira 对恐慌症患者健康结果和医疗保健成本的影响。

恐慌症 (PD) 是一种使人衰弱的疾病，其医疗支出至少是医学匹配对照组的两倍。医疗资源的过度利用来自急诊科 (ED)、药物、诊断测试和医生就诊。Freespira 是一种 FDA 批准的数字疗法，通过纠正潜在的异常呼吸生理机能来治疗 PD 和惊恐发作 (PA)。Freespira 的功效已在先前的研究中得到证实。本文报告了一项质量改进计划，该计划调查了使用 Freespira 治疗 PD 患者是否会在 12 个月内降低医疗成本并改善结果。使用恐慌症严重程度量表（PDSS）评估恐慌症状。治疗前和治疗后的保险索赔决定了费用。在基线时，平均临床医生总体印象 (CGI-S) 为 4。4（中度/重度病），平均 PDSS 为 14.4，平均 PA 频率/周为 2（范围 0-5）。治疗后立即（第 5 周）平均 CGI-S、PDSS 和每周 PA 频率下降至 2.8（临界/轻度疾病，分别为 4.9（缓解）和 0.2（范围 0-2），p < 0.001。82% 报告 PDSS 下降≥ 40%（临床显着），86% 无 PA。治疗一年后平均 CGI-S、PDSS 和 PA 分别保持在 2.1、4.4 和 0.3（范围 0-1）的低水平。91% 有 PDSS减少 ≥ 40%，73% 没有 PA。大多数患者在 Freespira 治疗后 1 年没有惊恐发作和/或减少了他们的症状和回避行为。平均总体医疗费用降低了 35%，从 548 美元降至 358 美元PMPM（每个成员每月）或每年减少 $2280。在治疗后 12 个月。ED 成本从 PMPM 的 87 美元减少到 30 美元，降低了 65%。药房成本中位数从 73 美元 PMPM 降低到 23 美元，降低了 68%。